The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells
Abstract
The targeted inhibition of antiapoptotic factors in tumour cells may provide a rational approach towards the development of novel anticancer therapies. Using human papillomavirus (HPV)-transformed cells as a model system, we investigated if RNA interference (RNAi)-mediated gene silencing can be employed in order to overcome the apoptosis resistance of cancer cells. We found that both vector-borne and synthetic small interfering (si)RNAs, specifically directed against the antiapoptotic HPV E6 oncogene, restored dormant tumour suppressor pathways in HPV-positive cancer cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive apoptotic cell death, selectively in HPV-positive tumour cells. These findings show that RNAi provides a powerful molecular strategy to inactivate intracellular E6 function efficiently. Moreover, they define E6 as a most promising therapeutic target to eliminate HPV-positive tumour cells specifically by RNAi. Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“blocking the expression of E6 and E7 has been shown to inhibit tumour cell proliferation, leading to senescence and apoptosis [17,18,19]”
From The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis (2021) · cites this paper as [17]
In the citing paper
“the silencing or repression of these oncoproteins activates senescence and apoptosis of the HPV-transformed cells [17,18,19,122,123]”
From The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis (2021) · cites this paper as [17]
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
Research works printed but not linked: 40
- Agami R . (2002). Curr. Opin. Chem. Biol., 6, 829–834. · DOI
- Brummelkamp TR, Bernards R and Agami R . (2002a). Cancer Cell, 2, 243–247. · DOI · Paper page
- Brummelkamp TR, Bernards R and Agami R . (2002b). Science, 296, 550–553. · DOI
- Butz K, Denk C, Ullmann A, Scheffner M and Hoppe-Seyler F . (2000). Proc. Natl. Acad. Sci. USA, 97, 6693–6697. · DOI
- Butz K, Geisen C, Ullmann A, Zentgraf H and Hoppe-Seyler F . (1998). Oncogene, 17, 781–787. · DOI
- Chen C and Okayama H . (1987). Mol. Cell. Biol., 7, 2745–2752. · DOI
- Chomczynski P and Sacchi N . (1987). Anal. Biochem., 162, 156–159. · DOI
- Cole ST and Danos O . (1987). J. Mol. Biol., 193, 599–608. · DOI
- Elbashir SM, Harboth J, Lendeckel W, Yalcin A, Weber K and Tuschl T . (2001). Nature, 411, 494–498. · DOI · Paper page
- Elbashir SM, Harboth J, Weber K and Tuschl T . (2002). Methods, 26, 199–213. · DOI
- El-Deiry WS, Tokino T, Velculescu VE, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825. · DOI · Paper page
- Evan GI and Vousden KH . (2001). Nature, 411, 342–348. · DOI · Paper page
- Fulda S, Wick W, Weller M and Debatin M . (2002). Nat. Med., 8, 808–815. · DOI
- Funk WD, Pak DT, Karas RH, Wright WE and Shay JW . (1992). Mol. Cell. Biol., 12, 2866–2871. · DOI
- Goodwin EC and DiMaio D . (2000). Proc. Natl. Acad. Sci. USA, 97, 12513–12518. · DOI · Paper page
- Igney FH and Krammer PH . (2002). Nat. Rev. Cancer, 2, 277–288. · DOI
- Jaque J-M, Triques K and Stevenson M . (2002). Nature, 418, 435–438. · DOI
- Jiang M and Milner J . (2002). Oncogene, 21, 6041–6048. · DOI
- Lee NS, Dohjima T, Bauer G, Li H, Li M-J, Ehsani A, Salvaterra P and Rossi J . (2002). Nat. Biotechnol., 19, 500–505. · DOI
- Mantovani F and Banks L . (2001). Oncogene, 20, 7874–7887. · DOI
- Mittnacht S . (1998). Curr. Opin. Genet. Dev., 8, 21–27. · DOI
- Morris MC, Chaloin L, Heitz F and Divita G . (2000). Curr. Opin. Biotechnol., 11, 461–466. · DOI
- Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M and Zacny VL . (2001). Oncogene, 20, 7888–7898. · DOI
- Nicholson DW . (2000). Nature, 407, 810–816. · DOI
- Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee S-K, Collman RG, Lieberman J, Shankar P and Sharp PA . (2002). Nat. Med., 8, 681–686. · DOI
- Paddison PJ and Hannon GJ . (2002). Cancer Cell, 2, 17–23. · DOI
- Pan H and Griep AE . (1994). Genes Dev., 9, 2157–2169. · DOI
- Parkin DM, Bray FI and Devesa SS . (2001). Eur. J. Cancer, 37, S4–S66. · DOI · Paper page
- Reed JC . (2001). Trends Mol. Med., 7, 314–319. · DOI
- Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R and Jacobs E . (2002). Mol. Ther., 5, 104–114. · DOI
- Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender P and Khavari PA . (2000). Nat. Med., 11, 1253–1257. · DOI
- Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM . (1990). Cell, 63, 1129–1136. · DOI · Paper page
- Schneider-Gaedicke A and Schwarz E . (1986). EMBO J., 5, 2285–2292. · DOI
- Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR and Schiller JT . (1991). J. Virol., 65, 4860–4866. · DOI
- Smotkin D, Prokoph H and Wettstein FO . (1989). J. Virol., 63, 1441–1447. · DOI
- Thomas M and Banks L . (1998). Oncogene, 17, 2943–2954. · DOI · Paper page
- Thomas M and Banks L . (1999). Oncogene, 18, 7690–7700. · DOI
- Venturini F, Braspenning J, Homann M, Gissmann L and Sczakiel G . (1999). Nucleic Acids Res., 27, 1585–1592. · DOI
- Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD and Howley PM . (2000). EMBO J., 19, 5762–5771. · DOI
- Zur Hausen H . (2002). Nat. Rev. Cancer, 2, 342–350. · DOI
Cited by
Molecular biology of human papillomavirus infection and cervical cancer
Doorbar, J. (2006) · Clinical Science · doi:10.1042/cs20050369 · Cited by 1,072
Nominé, Y., Masson, M., Charbonnier, S., Zanier, K., Ristriani, T., Deryckère, F., Sibler, A.-P., Desplancq, D., Atkinson, R. A., Weiss, E., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.024 · Cited by 177
Self-citationBasukala, O., & Banks, L. (2021) · Viruses · doi:10.3390/v13101892 · Cited by 137
Metadata
- Authors
- Butz, K., Ristriani, T., Hengstermann, A., Denk, C., Scheffner, M., & Hoppe-Seyler, F.
- Venue
- Oncogene
- Published
- 2003-09-04
- Volume
- 22
- Issue
- 38
- Pages
- 5938-5945
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 283
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review